The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML). Dr Sallman notes that optimizing venetoclax duration is crucial and suggests that separating mutant versus wild-type groups is essential for pivotal strategies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
